BioNTech SE BNTX
NASDAQ BNTX
$103.76 +0.88 (+0.86%)
As of: Sep 4, 2026 · 3:59 PM EDT

BioNTech SE (BNTX) Operating Income Growth (3y) (2021 - 2026)

Analysis

BioNTech SE (BNTX) Operating Income Growth (3y) (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 8.36%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 89.72%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -18.82%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 81.27%
10 BioNTech SE 25.06 Bn 11.41 Bn 10.00 Mn -21.57%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -21.57%
Mar 31, 2026 -46.27%
Dec 31, 2025 -28.30%
Sep 30, 2025 -26.47%
Jun 30, 2025 -30.85%
Mar 31, 2025 -28.17%
Dec 31, 2024 -69.09%
Sep 30, 2024 -87.26%
Jun 30, 2024 -30.17%
Mar 31, 2024 -31.52%
Dec 31, 2023 24.82%
Sep 30, 2023 -28.50%
Jun 30, 2023 -107.11%
Mar 31, 2023 120.56%
Dec 31, 2022 127.59%
Sep 30, 2022 288.57%
Jun 30, 2022 252.60%
Mar 31, 2022 374.83%
Dec 31, 2021 260.18%
Sep 30, 2021 504.98%